Literature DB >> 23440553

New agents in the arsenal to fight castrate-resistant prostate cancer.

Erin E Ezzell1, Kuang S Chang, Benjamin J George.   

Abstract

Prior to 2010, the treatment options for castrate-resistant prostate cancer (CRPC) were limited. In the past 3 years, four new agents have been approved by the US Food and Drug Administration for use in CRPC. These four agents differ in their mechanisms of action and highlight the progress made in our understanding of CRPC, and more importantly, provide options with proven clinical benefit. This review examines the development, investigational evolution, adverse events, and future direction of: 1) the androgen receptor inhibitor, enzalutamide, 2) androgen biosynthesis inhibitor, abiraterone, 3) novel taxane chemotherapy, cabazitaxel, and 4) autologous immunotherapeutic agent, sipuleucel-T.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23440553     DOI： 10.1007/s11912-013-0305-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  41 in total

1.  Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.

Authors:  L Fong; C L Ruegg; D Brockstedt; E G Engleman; R Laus
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

Authors:  Simon J Hall; Laurence Klotz; Allan J Pantuck; Daniel J George; James B Whitmore; Mark W Frohlich; Robert B Sims
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

4.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

7.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

10.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544
View more
  7 in total

1.  Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.

Authors:  Mikhail Krasavin; Andrey V Sosnov; Ruben Karapetian; Igor Konstantinov; Olga Soldatkina; Elena Godovykh; Fedor Zubkov; Ruoli Bai; Ernest Hamel; Andrei A Gakh
Journal:  Bioorg Med Chem Lett       Date:  2014-08-08       Impact factor: 2.823

2.  One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.

Authors:  Hossein Jadvar; Sudha Challa; David I Quinn; Peter S Conti
Journal:  Cancer Biother Radiopharm       Date:  2015-03-06       Impact factor: 3.099

Review 3.  The biology of castration-resistant prostate cancer.

Authors:  Fei Lian; Nitya V Sharma; Josue D Moran; Carlos S Moreno
Journal:  Curr Probl Cancer       Date:  2014-11-25       Impact factor: 3.187

Review 4.  Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.

Authors:  Georgios Kallifatidis; James J Hoy; Bal L Lokeshwar
Journal:  Semin Cancer Biol       Date:  2016-06-28       Impact factor: 15.707

5.  Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells.

Authors:  Varinder Jeet; Gregor Tevz; Melanie Lehman; Brett Hollier; Colleen Nelson
Journal:  Endocr Relat Cancer       Date:  2014-06-30       Impact factor: 5.678

6.  The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.

Authors:  Weranja K B Ranasinghe; Shomik Sengupta; Scott Williams; Mike Chang; Arthur Shulkes; Damien M Bolton; Graham Baldwin; Oneel Patel
Journal:  Cancer Med       Date:  2014-01-27       Impact factor: 4.452

7.  Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.

Authors:  Monica Vidal; Alejandro Delgado; Carlos Martinez; José Jaime Correa; Isabel Cristina Durango
Journal:  Int Braz J Urol       Date:  2020-03-15       Impact factor: 1.541
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.